| Jun 12 |
Ultragenyx (RARE) Posts New Data From Bone Disease Study
|
| Jun 12 |
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
|
| Jun 12 |
Ultragenyx, Mereo drug reduces fractures in bone disorder study
|
| Jun 11 |
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
|
| Jun 6 |
Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
|
| Jun 6 |
Ultragenyx upped at Goldman Sachs on bone disorder treatment
|
| Jun 4 |
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 31 |
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
|
| May 30 |
Ultragenyx Phase 3 study for DTX401 meets primary endpoint
|
| May 30 |
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
|
